Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ImmuCell

DB:IUL
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IUL
DB
$29M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • ImmuCell has significant price volatility in the past 3 months.
IUL Share Price and Events
7 Day Returns
2.8%
DB:IUL
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-34.4%
DB:IUL
-7.4%
DE Biotechs
-14.2%
DE Market
IUL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ImmuCell (IUL) 2.8% -13% -19.6% -34.4% -25.8% -
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • IUL underperformed the Biotechs industry which returned -7.4% over the past year.
  • IUL underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
IUL
Industry
5yr Volatility vs Market
Related Companies

Value

 Is ImmuCell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ImmuCell. This is due to cash flow or dividend data being unavailable. The share price is €3.62.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ImmuCell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ImmuCell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IUL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.19
NasdaqCM:ICCC Share Price ** NasdaqCM (2020-04-08) in USD $4
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ImmuCell.

DB:IUL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:ICCC Share Price ÷ EPS (both in USD)

= 4 ÷ -0.19

-21.05x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImmuCell is loss making, we can't compare its value to the Europe Biotechs industry average.
  • ImmuCell is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does ImmuCell's expected growth come at a high price?
Raw Data
DB:IUL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -21.05x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ImmuCell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ImmuCell's assets?
Raw Data
DB:IUL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $4.02
NasdaqCM:ICCC Share Price * NasdaqCM (2020-04-08) in USD $4
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:IUL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:ICCC Share Price ÷ Book Value per Share (both in USD)

= 4 ÷ 4.02

1x

* Primary Listing of ImmuCell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImmuCell is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess ImmuCell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ImmuCell has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ImmuCell expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmuCell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
38.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ImmuCell expected to grow at an attractive rate?
  • Unable to compare ImmuCell's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ImmuCell's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare ImmuCell's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:IUL Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IUL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IUL Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 14 0 -1
2019-09-30 13 0 -2
2019-06-30 12 0 -2
2019-03-31 13 0 -2
2018-12-31 11 0 -2
2018-09-30 11 0 -1
2018-06-30 11 0 -2
2018-03-31 10 0 -1
2017-12-31 10 1 0
2017-09-30 10 0 0
2017-06-30 9 1 0
2017-03-31 10 1 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ImmuCell is high growth as no earnings estimate data is available.
  • Unable to determine if ImmuCell is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IUL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ImmuCell Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IUL Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.19
2019-09-30 -0.32
2019-06-30 -0.30
2019-03-31 -0.35
2018-12-31 -0.42
2018-09-30 -0.27
2018-06-30 -0.30
2018-03-31 -0.19
2017-12-31 -0.03
2017-09-30 0.01
2017-06-30 0.09
2017-03-31 0.14

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ImmuCell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine ImmuCell's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. ImmuCell's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. ImmuCell's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ImmuCell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ImmuCell has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ImmuCell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ImmuCell's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ImmuCell does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ImmuCell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ImmuCell's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ImmuCell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ImmuCell Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IUL Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 13.72 -1.30 4.01 3.69
2019-09-30 13.03 -2.04 3.96 3.98
2019-06-30 12.21 -1.78 3.95 3.90
2019-03-31 12.52 -1.96 3.89 3.84
2018-12-31 10.99 -2.32 3.82 3.52
2018-09-30 11.18 -1.46 3.66 2.99
2018-06-30 11.03 -1.55 3.60 2.66
2018-03-31 9.77 -0.97 3.48 2.29
2017-12-31 10.43 -0.17 3.42 2.05
2017-09-30 9.51 0.06 3.37 1.57
2017-06-30 9.48 0.43 3.39 1.29
2017-03-31 10.10 0.64 3.42 1.28
2016-12-31 9.54 0.51 3.29 1.24
2016-09-30 10.02 0.77 3.31 1.32
2016-06-30 10.53 1.08 3.14 1.32
2016-03-31 10.11 1.19 2.95 1.21
2015-12-31 10.23 1.21 2.89 1.24
2015-09-30 9.74 1.06 2.71 1.37
2015-06-30 9.04 0.71 2.70 1.43
2015-03-31 8.62 0.33 2.63 1.92
2014-12-31 7.60 -0.17 2.48 2.18
2014-09-30 6.95 -0.45 2.29 2.04
2014-06-30 6.42 -0.40 2.10 1.97
2014-03-31 6.24 -0.10 2.01 1.48
2013-12-31 6.01 0.12 1.93 1.15
2013-09-30 5.87 0.25 1.94 1.06
2013-06-30 5.71 0.13 1.94 1.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ImmuCell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ImmuCell has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ImmuCell improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ImmuCell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ImmuCell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ImmuCell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ImmuCell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ImmuCell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ImmuCell's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ImmuCell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ImmuCell Company Filings, last reported 3 months ago.

DB:IUL Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 28.99 8.48 8.77
2019-09-30 29.19 8.72 9.55
2019-06-30 29.65 8.90 9.97
2019-03-31 30.25 9.06 10.58
2018-12-31 21.74 9.77 2.52
2018-09-30 22.67 9.48 2.39
2018-06-30 22.81 9.12 2.51
2018-03-31 23.49 9.19 3.06
2017-12-31 23.59 8.96 3.80
2017-09-30 20.95 5.90 2.31
2017-06-30 20.20 4.26 4.34
2017-03-31 20.37 3.29 7.23
2016-12-31 19.72 3.05 10.62
2016-09-30 16.41 3.25 9.61
2016-06-30 16.31 3.30 10.35
2016-03-31 16.32 3.30 10.51
2015-12-31 10.61 3.26 6.04
2015-09-30 10.30 3.38 6.19
2015-06-30 9.90 0.83 3.91
2015-03-31 9.74 0.89 4.21
2014-12-31 9.26 0.94 3.34
2014-09-30 9.12 0.98 4.15
2014-06-30 9.10 1.03 4.69
2014-03-31 9.39 1.08 4.98
2013-12-31 9.40 1.12 5.26
2013-09-30 9.51 1.18 5.67
2013-06-30 9.45 1.22 5.68
  • ImmuCell's level of debt (29.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (10.1% vs 29.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ImmuCell has sufficient cash runway for more than 3 years based on current free cash flow.
  • ImmuCell has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.1% each year.
X
Financial health checks
We assess ImmuCell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ImmuCell has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ImmuCell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ImmuCell dividends.
If you bought €2,000 of ImmuCell shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ImmuCell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ImmuCell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IUL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ImmuCell has not reported any payouts.
  • Unable to verify if ImmuCell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ImmuCell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ImmuCell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ImmuCell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ImmuCell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ImmuCell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ImmuCell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Brigham
COMPENSATION $426,275
AGE 58
TENURE AS CEO 20.2 years
CEO Bio

Mr. Michael F. Brigham has been the Chief Executive Officer and President of Immucell Corp. since February 2000 and its Principal Financial Officer and Treasurer since October 1991. Mr. Brigham has been Secretary of Immucell Corp. since December 1995. He serves as Treasurer of the Board of Trustees of the Kennebunk Free Library. He served as Vice President of Immucell Corp. from December 1998 to February 2000. He served as Director of Finance and Administration of Immucell Corp. since September 1989. He served as an Audit Manager for the public accounting firm of Ernst & Young. He serves on the Board of Directors of the Biotechnology Association of Maine. He has been a Director of Immucell Corp. since March 1999. He serves on the Board of Directors of the Maine Biotechnology Information Bureau. He Earned a Bachelor of Arts Degree from Trinity College in Hartford, Connecticut in 1983 and his Masters in Business Administration from New York University in 1989.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the ImmuCell management team in years:

12.7
Average Tenure
60.5
Average Age
  • The average tenure for the ImmuCell management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Michael Brigham

TITLE
President
COMPENSATION
$426K
AGE
58
TENURE
20.2 yrs

Joseph Crabb

TITLE
VP & Chief Scientific Officer
COMPENSATION
$62K
AGE
64
TENURE
21.6 yrs

Kunde Brockmann

TITLE
VP of Sales & Marketing and Director
COMPENSATION
$292K
AGE
42
TENURE
5.2 yrs

Betsy Williams

TITLE
Vice President of Manufacturing Operations
COMPENSATION
$274K
AGE
63
TENURE
4 yrs
Board of Directors Tenure

Average tenure and age of the ImmuCell board of directors in years:

7.2
Average Tenure
54
Average Age
  • The tenure for the ImmuCell board of directors is about average.
Board of Directors

David Tomsche

TITLE
Chairman
COMPENSATION
$84K
AGE
62
TENURE
7.2 yrs

Michael Brigham

TITLE
President
COMPENSATION
$426K
AGE
58
TENURE
21.1 yrs

Kunde Brockmann

TITLE
VP of Sales & Marketing and Director
COMPENSATION
$292K
AGE
42
TENURE
2.3 yrs

David Cunningham

TITLE
Independent Director
COMPENSATION
$72K
AGE
53
TENURE
8.6 yrs

Paul Wainman

TITLE
Independent Director
COMPENSATION
$72K
AGE
54
TENURE
6.1 yrs

Jonathan Rothschild

TITLE
Independent Director
COMPENSATION
$72K
AGE
65
TENURE
19 yrs

Steven Rosgen

TITLE
Independent Director
COMPENSATION
$66K
AGE
53
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ImmuCell individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Mar 20 Buy David Cunningham Individual 12. Mar 20 12. Mar 20 2,000 €3.61 €7,230
12. Mar 20 Buy David Tomsche Individual 11. Mar 20 11. Mar 20 4,600 €3.80 €17,469
02. Mar 20 Buy David Tomsche Individual 27. Feb 20 27. Feb 20 5,130 €4.54 €23,276
X
Management checks
We assess ImmuCell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ImmuCell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

Details
Name: ImmuCell Corporation
IUL
Exchange: DB
Founded: 1982
$26,532,001
7,212,919
Website: http://immucell.com
Address: ImmuCell Corporation
56 Evergreen Drive,
Portland,
Maine, 04103,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM ICCC Common Stock Nasdaq Capital Market US USD 01. May 1987
DB IUL Common Stock Deutsche Boerse AG DE EUR 01. May 1987
Number of employees
Current staff
Staff numbers
53
ImmuCell employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 23:08
End of day share price update: 2020/04/08 00:00
Last earnings filing: 2020/03/27
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.